{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T01:31:57Z","timestamp":1777167117417,"version":"3.51.4"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Most patients with anaplastic lymphoma kinase-positive (<jats:italic>ALK+<\/jats:italic>) non-small-cell lung cancer (NSCLC) could benefit from the treatment with selected tyrosine kinase inhibitors (TKIs) for a period of time, but almost inevitably progress due to drug resistance. It was reported that these patients were generally unresponsive to immune-based therapies. Here, we reported that stereotactic body radiotherapy (SBRT) combined with pneumococcal conjugate vaccine (PCV) produced excellent therapeutic outcomes in a patient after multiple lines of TKI treatment. The patient\u2019s metastasis lesion experienced regression after SBRT for lumbar spine. Unexpectedly, the patient also experienced an abscopal complete pathological response (CPR) just after combination use of SBRT and PCV. Biopsy analysis indicated that the primary lung lesion was map-like necrotic and infiltrated by tumor-infiltrating lymphocytes (TILs), and multifocal granulomas and early tertiary lymphoid structures (TLS) were formed. Our case reported that radiotherapy plus PCV could specifically stimulate immune response and remodel the tumor immune microenvironment in TKI-resistant NSCLC, which may provide a new perspective for future immunotherapy in this challenging clinical situation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.950252","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T05:32:28Z","timestamp":1660195948000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Case report: Radiotherapy plus pneumococcal conjugate vaccine stimulates abscopal immune response in a patient with ALK+ NSCLC"],"prefix":"10.3389","volume":"13","author":[{"given":"Yong-Sheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ze-Fen","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00077-7","article-title":"Genomic alterations in lung adenocarcinoma","volume":"16","author":"Devarakonda","year":"2015","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc2291","article-title":"The anaplastic lymphoma kinase in the pathogenesis of cancer","volume":"8","author":"Chiarle","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.023","article-title":"Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249 insertion in three patients with NSCLC after ALK tyrosine kinase inhibitor treatment","volume":"16","author":"Furuta","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.3390\/cancers13061476","article-title":"Immunotherapy for ALK-rearranged non-small cell lung cancer: Challenges inform promising approaches","volume":"13","author":"Sankar","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"Cancer therapy: Clinical EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway. blockade in non-small cell lung cancer: A retrospective analysis. clin","volume":"22","author":"Gainor","year":"2016","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.cllc.2020.08.003","article-title":"Immunotherapy treatment patterns and outcomes among ALK-positive patients with non\u2013Small-Cell lung cancer","volume":"22","author":"Jahanzeb","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0246-1","article-title":"Inflammatory microenvironment remodelling by tumour cells after radiotherapy","volume":"20","author":"McLaughlin","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.038","article-title":"Pneumococcal conjugate vaccine use during humanitarian crises","volume":"37","author":"van Zandvoort","year":"2019","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e004371","DOI":"10.1136\/jitc-2021-004371","article-title":"Spontaneous tumor regression following COVID-19 vaccination","volume":"10","author":"Sousa","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.950252\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T05:32:31Z","timestamp":1660195951000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.950252\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,11]]},"references-count":14,"alternative-id":["10.3389\/fimmu.2022.950252"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.950252","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,11]]},"article-number":"950252"}}